Drug Approval | January 21, 2022
Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Biocon has reported consolidated financial results for the period ended December 31, 2021
The stability is led by healthy demand in the domestic and emerging markets
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
The transaction is expected to close in the first quarter of 2022
It is the generic version of molnupiravir
Biogen paid Ionis a US $ 60 million one-time upfront payment
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
Subscribe To Our Newsletter & Stay Updated
